NCT03797014已完成4 期
Efficacy, Safety, and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-HBV Coinfection
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- HBV DNA at Week 24
研究概览
简要总结
The primary objective of this study is to evaluate the efficacy and safety of fixed dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults coinfected with both HIV-1 and hepatitis B. As this is a switch study, all eligible subjects enrolled will be switched from their current antiretroviral regimen to B/F/TAF will be followed on treatment for 48 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
This is an open label study
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older at enrollment.
- •Documented HIV-1 infection and currently on a stable regimen for at least 3 months if on an INSTI-based regimen (6 months if on a non-INSTI-based regimen) preceding the screening visit with documented plasma HIV-1 RNA ≤ 50 copies/mL for at least 3 months preceding the screening visit.
- •No known history of resistance to tenofovir alafenamide (TAF), emtricitabine (FTC), or Bictegravir (BIC).
- •Documented chronic hepatitis B infection, based on any of the following: a. Positive HBsAg result or nucleic acid test for HBV DNA (including qualitative, quantitative, and genotype testing) or positive HBeAg on two occasions at least 6 months apart (any combination of these tests performed 6 months apart is acceptable); or b. Negative immunoglobulin M (IgM) antibodies to HBV core antigen (anti-HBc IgM) AND a positive results on one of the following tests: HBsAg, HBeAg, or nucleic acid test for HBV DNA (including qualitative, quantitative, and genotype testing) prior to or at screening.
- •No current or prior regimen containing three active anti-HBV agents (i.e. cannot be on tenofovir alafenamide (TDF)/emtricitabine (FTC)/entecavir or TDF/lamivudine (3TC)/entecavir).
- •Must have a primary care provider(s) for medical management.
- •Females of childbearing potential must agree to utilize protocol recommended highly effective contraceptive methods or be non-heterosexually active or practice sexual abstinence from screening and throughout the duration of the study. Female subjects who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least 3 months prior to study drug dosing.
- •Male subjects must be willing to abstain from heterosexual intercourse or use a condom throughout the study period.
- •Stated willingness to comply with all study procedures and availability for the duration of the study.
- •Written informed consent must be obtained before any study procedure is performed.
排除标准
- •Females who are pregnant or breastfeeding.
- •Any known allergies to any of the components of B/F/TAF.
- •Treatment with another investigational drug within three months of enrollment.
- •Abnormal hematological and biochemical parameters at screening, including:
- •Absolute neutrophil count (ANC) < 750 cells/mm
- •Platelets < 50,000/mm
- •Hemoglobin < 8.5 g/dL.
- •AST or ALT of > 5 times upper limit of normal (ULN).
- •Estimated GFR < 30 mL/min/1.73 m
- •Total bilirubin > 1.5 times ULN.
- •Previous or current history of malignancy, other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma. Note: Those with a history of malignancy who are in remission for two or more years may be included in the study.
- •An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening.
- •Subjects experiencing decompensated cirrhosis (e.g. ascites, encephalopathy, or variceal bleeding).
- •Acute hepatitis in the 30 days prior to study entry.
- •Active tuberculosis infection.
- •Subjects receiving ongoing therapy with any medications contraindicated for co-administration with B/F/TAF FDC, including but not limited to the following medications: dofetilide, phenobarbital, phenytoin, carbamazepine, oxcarbamazepine, rifampin, rifapentine, cisapride, St. John's Wort, and Echinaceae.
- •Current alcohol or substance use that in the opinion of the investigator may interfere with subject study compliance.
- •Any other clinical conditions that in the opinion of the investigator would make the subject unsuitable for the study or unable to comply with the dosing requirements.
研究组 & 干预措施
B/F/TAF
Experimental
Treatment group (1-arm study)
干预措施: B/F/TAF (Drug)
结局指标
主要结局
HBV DNA at Week 24
时间窗: Week 24
Proportion of participants with plasma HBV DNA \<29 IU/mL at Week 24 as defined by Missing=Failure Approach
HIV-1 RNA at Week 24
时间窗: Week 24
Proportion of participants with HIV-1 RNA \<50 copies/mL at Week 24 by US FDA Snapshot Algorithm
次要结局
- HBeAg Loss at Week 48(Week 48)
- HIV-1 RNA at Week 48(Week 48)
- CD4 Cell Count Change at Week 24(Baseline; Week 24)
- ALT Normalization at Week 48(Week 48)
- HBsAg Loss at Week 48(Week 48)
- HBV DNA at Week 48(Week 48)
- CD4 Cell Count Change at Week 48(Baseline; Week 48)
- ALT Normalization at Week 24(Week 24)
研究者
Joel Chua
Assistant Professor of Medicine
University of Maryland, Baltimore
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.Essential HypertensionNCT05288400Servier150
已完成
3 期
Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in HypertensionHypertensionNCT05820880Institut de Recherches Internationales Servier532
进行中（未招募）
不适用
Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Taken as 5 Days Per WeekVirally Suppressed People With HIVNCT06773754National Taiwan University Hospital60
已完成
2 期
Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsHIV-1 InfectionNCT02397694Gilead Sciences98
已完成
1 期
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected ParticipantsHIV-1 InfectionNCT02275065Gilead Sciences23